Podcast Index
Browse podcasts by category, open recent episodes, and download audio to listen offline.
The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus
BZ Group
The Archaeology Podcast Network Feed
The Archaeology Podcast Network
Galactic Horrors
Galactic Horrors
West Palm Beach Weather Daily
Fast Foundations
Montreal Weather Daily
Fast Foundations
Toronto Weather Daily
Fast Foundations
Philadelphia Weather Daily
Fast Foundations
Fascinating Frontiers
Patrick
God's Eye View
Trevor
Chicago Weather Daily
Fast Foundations
Clima Diario Ciudad de México
Fast Foundations
Daily Short Stories - Ghost and Horror Stories
Sol Good Network
Neville Goddard Daily
Neville Goddard
Science Fiction - Daily Short Stories
Sol Good Network
Stories - Science Fiction
Sol Good Network
Daily Science Fiction Stories
solgoodmedia.com
Daily Ghost and Horror Stories
solgoodmedia.com
SciFi Cast
solgoodmedia.com
Mind Webs Radio
solgoodmedia.com
Mind Webs
solgoodmedia.com
Quiet Please
Wyllis Cooper
The Adventures of Superman
Dashiell Hammett
Old Time Science Fiction
solgoodmedia.com
Vintage Sci-Fi Radio
solgoodmedia.com
Classic Radio Science Fiction
solgoodmedia.com
Interstellar Sci-Fi Tunes
solgoodmedia.com
Time Traveler's Radio
solgoodmedia.com
Science Fiction Radio
solgoodmedia.com
Classic Radio Science Fiction
solgoodmedia.com
Science Fiction Radio Hour
solgoodmedia.com
Pioneer Sci-Fi Radio
solgoodmedia.com
Timeless Sci-Fi Radio
solgoodmedia.com
Galactic Sci-Fi Broadcasts
solgoodmedia.com
Future Worlds Radio
solgoodmedia.com
Daily Short Stories - Science Fiction
Public Domain Books
Relativity: The Special & General Theory
Albert Einstein
Mind Webs - Old Time Audio
Michael Hanson
Science
BZ Group
Roche's divarasib beats both KRAS G12C rivals on PFS and OS in head-to-head Phase 3, hitting survival significance at interim. AstraZeneca returns to CSPC in a $1.7B siRNA kidney disease deal; Abivax surges on $920M rais...
FDA approves Orca Bio's Tregzi — the first precision-engineered cell therapy for allogeneic transplant, sparking IPO speculation. Plus BridgeBio secures $1B from Sixth Street and KKR at a 100%+ conversion premium, Ipsen'...
NEJM retracts Amgen's ADVOCATE study after FDA findsendpoint data for 9 patients re-evaluated post-unblinding. Plus: Ionis faces the Tryngolza sNDA PDUFA in severe hypertriglyceridemia, AbbVie's Epkinly delivers chemo-fr...
Lilly at $1,230 — trading above analyst consensus — as orforglipron faces its FDA verdict tomorrow. Three label items to watch beyond the headline, plus healthcare's dramatic sub-sector bifurcation: drug makers up 25% YT...
FDA breaks Amgen's Tepezza monopoly with Viridian's Lumvoa approval in thyroid eye disease. Plus Merck KGaA's $11.3B Bio-Techne acquisition, Biogen gutting the Apellis pipeline post-$5.6B deal, CHMP moves to revoke Tavne...
FDA approves Ionis Tryngolza as first treatment to reduce pancreatitis risk in severe hypertriglyceridemia — a potential blockbuster expansion. Merck KGaA acquires Bio-Techne for $11.3B in largest deal in a decade. SCOTU...
Gilead's Trodelvy wins front-line triple-negative breast cancer approval — and the stock barely moves. Lilly expands its Abbisko partnership to $1.9B, Novartis pays $105M upfront to Antares for undruggable cancer targets...
Pfizer's sigvotatug vedotin disappoints in Phase 3 NSCLC — another blow to the $43B Seagen deal. Plus CMS settles with Incyte on Opzelura classification, Sangamo Therapeutics closes after 30 years, and Moderna's flu vacc...
AbbVie bets $10.9B on Apogee Therapeutics to challenge Dupixent — its biggest deal since Allergan. Plus: the first CAR-T approved for a solid tumor clears in China, Merck's $10.8B Prometheus IBD bet pays off with a Phase...
US government opens formal probe into Germany's drug pricing reforms, escalating transatlantic pharma trade tensions. Kardigan IPO raises $400M and pops 31%. Moderna flu vaccine gets unanimous FDA advisory panel support ...
Moderna's mRNA flu vaccine gets unanimous FDA panel backing — PDUFA August 5. NovoCure's TRIDENT trial misses overall survival in glioblastoma; stock drops ~18%. Biogen acquires immunology startup RayThera for up to $1B;...
UniQure surges 70% as FDA reverses course on Huntington's gene therapy AMT-130 filing path. Jazz and AbCellera strike $4.1B T cell engager deal for GI cancers. Novo Nordisk faces $25M ransom demand after hackers claim dr...
BridgeBio's BBP-418 sweeps Phase 3 in limb-girdle muscular dystrophy — stock up 15%, no approved competition. FDA briefing docs challenge Moderna mFlusiva efficacy ahead of Thursday's VRBPAC vote. Plus Lilly acquires non...
CMS proposes closing Medicare negotiation loophole threatening Keytruda and Opdivo subcutaneous strategies — billions at stake. Plus Takeda's zasocitinib tops Sotyktu, Novartis validates $12B Avidity deal, Elicio's KRAS ...
The Pharma Closeout's comprehensive recap of EHA 2026(Stockholm, June 11-14). HEADLINE: J&J's MonumenTAL-3 (talquetamab +daratumumab) in earlier-line R/R myeloma — PFS HR 0.28/0.33, complete-response 71% vs 34.5%, NEJM-p...
FDA approves Merck's Welireg-Keytruda combo for adjuvant kidney cancer — 28% risk reduction vs. active Keytruda monotherapy in LITESPARK-022. Jazz's Zepzelca misses OS endpoint in Phase 3 LAGOON, Incyte acquires Vega The...
Zasocitinib hits 35% complete skin clearance at week 16,topping Sotyktu by more than 2.5x in Takeda's head-to-head Phase 3. Plus: Novartis validates its $12B Avidity AOC platform in FSHD, Summit withdraws $500M offering,...
Parabilis Medicines prices the largest-ever venture-backed biotech IPO at $670M as 12 startups top $4.1B in 2026. Sanofi stops MOBILIZE Phase 3 for riliprubart in CIDP. TG Therapeutics surges on Briumvi myasthenia gravis...
The Pharma Closeout's full recap of the American Diabetes Association's 86th Scientific Sessions (New Orleans,June 5-8, 2026) - the meeting that ended the A1C-only era and reset what obesity medicine can do. Hosts Alex M...
In about six weeks this spring, four of the biggest names in pharma each picked an AI partner — Bristol Myers Squibb chose Anthropic's Claude for 30,000+ employees, Merck signed with Google Cloud for up to $1B, Novo Nord...
Fill in the form below. Make sure to select both Country and Genres.
Send us a message below. We will get back to you within 24 hours.